^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LCAR-AIO

    i
    Other names: LCAR-AIO, Tri-specific CD19xCD20xCD22 VHH CAR-T cells, LCARAIO, LCAR AIO
    Associations

    News

    Trials
    Company:
    Legend Biotech
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    5ms
    A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=0, Withdrawn, Nanjing Legend Biotech Co. | N=38 --> 0 | Trial completion date: Dec 2029 --> Jun 2025 | Initiation date: Feb 2025 --> Jun 2025 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2026 --> Jun 2025
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date
    |
    LCAR-AIO
    6ms
    A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases (clinicaltrials.gov)
    P1, N=37, Recruiting, Wuhan Union Hospital, China | Not yet recruiting --> Recruiting | Initiation date: Mar 2025 --> Jun 2025
    Enrollment open • Trial initiation date
    |
    LCAR-AIO
    6ms
    A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=10, Terminated, Institute of Hematology & Blood Diseases Hospital, China | N=20 --> 10 | Trial completion date: Jul 2026 --> Mar 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2024 --> Jan 2025; Achieve the proof of concept
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV • LCAR-AIO
    6ms
    Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=14, Terminated, Institute of Hematology & Blood Diseases Hospital, China | N=34 --> 14 | Trial completion date: Jun 2026 --> Mar 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jan 2025; The collaborators decided to terminate this study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV • LCAR-AIO
    9ms
    A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases (clinicaltrials.gov)
    P1, N=37, Not yet recruiting, Wuhan Union Hospital, China
    New P1 trial
    |
    LCAR-AIO
    9ms
    A Study of LCAR-AIO in Subjects with Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=38, Recruiting, Nanjing Legend Biotech Co.
    New P1 trial
    |
    LCAR-AIO
    11ms
    A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=34, Recruiting, Wuhan Union Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    LCAR-AIO
    1year
    A Study of LCAR-AIO in Subjects with Relapsed/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Wuhan Union Hospital, China
    New P1 trial
    |
    LCAR-AIO
    over1year
    A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting | N=34 --> 20
    Enrollment closed • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO
    over3years
    A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=34, Recruiting, Institute of Hematology & Blood Diseases Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO
    over3years
    Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=34, Recruiting, Qiu Lugui
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO
    over3years
    A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO